Navigation Links
Drug-Eluting Stents Outperform Bare Stents in Heart Attack
Date:3/30/2008

h heart attack because studies have reported conflicting results on the benefits of drug-eluting stents in this group of patients and have raised concerns over the risk of blood clotting inside the stent, or stent thrombosis. The new study has certain design advantages over previous studies, specifically its size and an enrollment and follow-up protocol that more closely reflects everyday clinical practice.

As for tirofiban and abciximab, both are in a class of medications known as glycoprotein 2b/3a inhibitors and prevent blood clotting by blocking hyperactivation of platelets. Tirofiban is an attractive alternative for several reasons: It is shorter-acting and is cleared from the body more readily than abciximab, it is less likely to cause a dangerous drop in the number of platelets in the blood, and it is far less expensive. However, previous studies have been too small or have used too low a dose of tirofiban to reach a definitive conclusion about which medication is better, Dr. Valgimigli said.

The new study, which involved 16 medical centers, enrolled 745 patients who were set to undergo PCI for STEMI. Patients were randomly assigned to an infusion of abciximab or high-dose tirofiban (25 microgram/kg) and, in a second round of randomization, to treatment with either uncoated or sirolimus-eluting stents.

To judge the effectiveness of tirofiban and abciximab, researchers examined electrocardiograms -- 722 of which were interpretable -- to determine the proportion of patients with at least a 50 percent return of the elevated "ST-segment" to its normal baseline. The results were equivalent in the two groups (83.6 percent in the abciximab group vs. 85.3 percent in the tirofiban group). In addition, there was no significant difference in the rate of major adverse cardiac events (MACE) -- a combination of death, repeat heart attack, and repeat procedure to open the treated coronary artery -- in the two groups: 4.8 percent vs. 4.5 percent, respect
'/>"/>

SOURCE SCAI-ACCi2
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
3. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
4. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
7. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
8. Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack
9. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
10. American Heart Association Journal Report: Reducing Kids Salt Intake May Lower Soft Drink Consumption, Reducing Obesity, High Blood Pressure and Later Health Risks
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014   Plexus Information ... of Anesthesia Information Management Systems (AIMS), announced a ... , a wholly owned subsidiary of Quality Systems, ... systems and connectivity solutions.  Logo ... This partnership extends the ...
(Date:10/1/2014)... -- ResMed (NYSE: RMD ), a pioneer and innovator ... complete sleep apnea solutions specifically for women, is launching a ... good night,s sleep. The Better Sleep For ... is just part of living a busy life. It will ... of health, essential to not only living an active lifestyle ...
(Date:10/1/2014)... 2014 Trovagene, Inc., (NASDAQ:  TROV) a ... Eli Diamond , MD, Assistant Attending Neurologist ... clinical data from an ongoing study demonstrating the ... the determination of oncogene mutational status in cell-free ... were presented to both treating physicians and patients ...
Breaking Medicine Technology:Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... SAN DIEGO, July 9 Arena Pharmaceuticals, ... results from a multiple-ascending,dose Phase 1b clinical ... safety,pharmacokinetics and pharmacodynamics. APD791 is Arena,s internally,discovered ... of arterial,thrombosis and other related conditions., ...
... July 8 After meeting on July 1st ... new diabetes drugs should,undergo trials to rule out ... US endocrinologists agree with this recommendation, according to,AlphaDetail ... market,research and key opinion leader mapping solutions to ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 4Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 5AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panel's Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications. 2
(Date:10/2/2014)... October 02, 2014 Social-Engineer, Inc. the ... announced today it will host a complimentary webinar on ... will reveal the final outcome of the annual Social-Engineer ... 22 in Las Vegas and explore how to maximize ... attacks. To register for the webinar go to: ...
(Date:10/2/2014)... Norton HealthDay Reporter WEDNESDAY, ... birth control -- especially long-acting implanted devices -- could slash ... average, new findings suggest. In a study of 1,400 ... cut the girls, rates of unplanned pregnancy and abortion. Over ... girls -- versus a rate of 158 per 1,000 among ...
(Date:10/2/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... major highway may raise your risk for high blood pressure, ... women, those who lived within 109 yards of a busy ... blood pressure than women living at least half a mile ... highlight the importance of our physical environment on our health ...
(Date:10/2/2014)... at The University of Nottingham could lead to the ... A drug resulting from the research, published in the ... hope to sufferers of chronic pain conditions such as ... currently available. , The work, led by Dr Lucy ... collaboration with David Bates, Professor of Oncology in the ...
(Date:10/1/2014)... the brain of a rat and a robot could ... QUT leading robotics researcher. , Dr Michael Milford ... study uses new computer algorithms to enable robots to ... "This is a very Frankenstein type of project," Dr ... thing together because we,re taking the eyes of a ...
Breaking Medicine News(10 mins):Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 2Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 3Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 2Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 3Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 4Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:Medical discovery first step on path to new painkillers 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2
... of a landmark study, researchers at Mayo Clinic,s Florida campus ... need to remove colon polyps that are not cancerous or ... to one-half of the polyps removed during colonoscopies end up ... and this increases time, expense and the potential for complications ...
... amo, a destination spa,at Enchantment Resort, for a ... winter solstice on December 21. Activities include a,series ... Program Director R.J. Joseph and special guest, Elder ... from the Blood Reserve,in Standoff, Alberta, Canada,s largest ...
... announcement of planned bequest comes at stem cell symposium, ... one year,ago, retail pioneer A. Alfred Taubman announced a ... a new research institute aimed at,understanding, treating and preventing ... he did it again --,announcing that he will bequeath ...
... Wanted to Know But Was Afraid to Ask!, ... babies born,in the U.S. each year but there,s not ... is a revealing, entertaining and inspirational DVD that,offers invaluable ... gone through the pregnancy and delivery process. It includes,a ...
... LAKE CITY University of Utah researchers have developed a ... to the wall of the heart,s left atrium in patients ... results of the study are published in the Oct. 7, ... of Cardiology . , Atrial fibrillation (AF) is an ...
... ) (OTCBB:WYND), the ideas-to-revenues social media company, ... ( www.muveinc.com ), to create an interactive ... activity-based corporate wellness program. Wyndstorm,s design project ... the use of wellness programs among employees ...
Cached Medicine News:Health News:Mayo Clinic estimates new, tiny, super-sensitive probe could cut colon polyp removal in half 2Health News:Mii amo Honors Winter Solstice With Traditional Native American Celebration December 18-21 2Health News:Alfred Taubman Announces New $22M Gift to U-M 2Health News:BEING DAD DVD Offers a Sneak Peek at Pregnancy From a Guy's Point of View 2Health News:Novel imaging approach may assist in predicting success of treatment for atrial fibrillation 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: